House Dust Mite Extract (Acarizax ®) for Allergic Rhinitis. HTA ID: 20015

Assessment Status Assessment process complete
HTA ID 20015
Drug House Dust Mite Extract
Brand Acarizax ®
Indication For the treatment of adult patients (18-65 years) diagnosed by clinical history and a positive test of HDM sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.
Assessment Process
Rapid review commissioned 12/03/2020
Rapid review completed 30/04/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of HDM extract compared with the current standard of care.

The company has not submitted a HTA dossier to the NCPE; therefore the cost-effectiveness of the technology could not be proven.